Catheter-based radiofrequency renal denervation significantly reduced blood pressure and urinary protein excretion at 12 months (P<.05) without adverse effects on renal artery structure.
Cohort (n=77)
Does catheter-based radiofrequency renal denervation reduce blood pressure and affect renal artery structure in patients with resistant hypertension?
Catheter-based radiofrequency renal denervation effectively lowers blood pressure and urinary protein in resistant hypertension without causing adverse structural changes to the renal arteries over 12 months.
p-value: p=<.05
There are no clinical studies on the effects of catheter-based radiofrequency renal denervation (RDN) on renal artery structure using 64-detector computed tomography (CT). A total of 39 patients with resistant hypertension received RDN and 38 patients received drug treatment. Mean systolic pressure and diastolic pressure in the RDN group decreased after 1, 3, 6, and 12 months of procedure (P<.05) and urinary protein level significantly decreased after 6 and 12 months (P<.05). The diameter, length, and sectional area of the renal artery; number of cases of atherosclerosis; and plaque burden of 64-detector CT renal arteriography did not change at 12 months of follow-up (P<.05), whereas the plaque burden increased significantly in the control group (P<.05). RDN significantly and persistently reduced blood pressure and decreased urinary protein excretion rate in patients with resistant hypertension and did not exhibit any adverse effect on renal function and renal artery structure.
Zhang et al. (Sat,) conducted a cohort in Resistant hypertension (n=77). Catheter-based radiofrequency renal denervation (RDN) vs. Drug treatment was evaluated on Mean systolic and diastolic blood pressure, urinary protein level, and renal artery structure (p=<.05). Catheter-based radiofrequency renal denervation significantly reduced blood pressure and urinary protein excretion at 12 months (P<.05) without adverse effects on renal artery structure.